A
Arif Khwaja
Researcher at Northern General Hospital
Publications - 37
Citations - 7061
Arif Khwaja is an academic researcher from Northern General Hospital. The author has contributed to research in topics: Kidney disease & Renal osteodystrophy. The author has an hindex of 14, co-authored 34 publications receiving 5283 citations. Previous affiliations of Arif Khwaja include King's College London & National Health Service.
Papers
More filters
Journal ArticleDOI
KDIGO clinical practice guidelines for acute kidney injury.
TL;DR: The guidelines focused on 4 key domains: (1) AKI definition, (2) prevention and treatment of AKI, (3) contrastinduced AKI (CI-AKI) and (4) dialysis interventions for the treatment ofAKI.
Journal ArticleDOI
Bone Disease after Kidney Transplantation
TL;DR: This review focuses on recent data that highlight improvements in understanding of the prevalence, pathophysiology, and diagnostic and therapeutic strategies of mineral and bone disorders in kidney transplant recipients.
Journal ArticleDOI
Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial
Sunil Bhandari,Natalie Ives,Elizabeth Brettell,Marie Valente,Paul Cockwell,Peter Topham,John G.F. Cleland,Arif Khwaja,Meguid El Nahas +8 more
TL;DR: Whether discontinuation of ACEi/ARBs can improve or stabilize renal function in patients with advanced progressive CKD will show whether this simple intervention can improve laboratory and clinical outcomes, including progression to end-stage renal disease, without causing an increase in cardiovascular events.
Journal ArticleDOI
Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy
TL;DR: The biomarkers bALP, intact PINP, and TRAP5b and radius HR-pQCT parameters can discriminate low from nonlow bone turnover and iPTH can discriminate high bone turnover with accuracy similar to that of the other biomarkers, including CTX.
Journal ArticleDOI
Prenylation inhibitors in renal disease
TL;DR: It is hypothesised that inhibition of prenylation could be of substantial therapeutic benefit in renal diseases, providing greater selectivity against abnormal cytokine-driven proliferation and fibrogenesis than current treatments available to nephrologists.